Autologous Neutralizing Antibodies Prevail in HIV-2 but Not in HIV-1 Infection

Björling, Ewa; Scarlatti, Gabriella; Gegerfelt, Agneta von; Albert, Jan; Biberfeld, Gunnel; Chiodi, Francesca; Norrby, Erling; Fenyõ, Éva Mária

doi:10.1006/viro.1993.1160

Cited by 83 publications

(51 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As shown in Table 2, approximately half of the isolates were susceptible to autologous 75% neutralization, similar to data reported for other primary HIV-1 isolates [18,[23][24][25], although the autologous neutralization of the B 00 -variant isolates was slightly higher than that observed for the B-subtype isolates. The low number of F-subtype isolates available for neutralization analyses does not allow an effective comparison with the other two HIV-1 subtypes studied.…”

Section: Susceptibility To Autologous Neutralizationsupporting

confidence: 84%

Neutralization Susceptibility of B Subtype Variant B′′ Primary HIV‐1 Isolates

Bongertz

et al. 1998

Scand J Immunol

View full text Add to dashboard Cite

Susceptibility to autologous and heterologous neutralization of primary human immunodeficiency virus (HIV)‐1 isolates belonging to subtype B, to the B′′‐variant of subtype B or to subtype F from infected individuals residing in Rio de Janeiro was assayed. A lower infectivity of the B′′‐ and F isolates when compared to the classical B‐subtype HIV‐1 isolates was observed. Comparisons of neutralization susceptibilities were carried out for 19 B‐subtype, 11 B′′‐variant and two F‐subtype HIV‐1 isolates with plasma from autologous and heterologous samples. Frequency of autologous neutralization was slightly lower for B‐subtype isolates in comparison to B′′‐variant isolates. Heterologous intra‐subtype neutralization was significantly lower for B‐subtype than for the B′′‐variant or the F‐subtype isolates. While B‐subtype isolates were neutralized by most anti‐F‐subtype plasma, F‐subtype isolates, although most susceptible to F‐subtype antibodies, were highly susceptible to neutralization by anti‐B‐subtype antibodies. Cross‐neutralization for B′′‐variant and B‐subtype isolates was not as extensive as observed for B‐ and F‐subtype isolates. However, the results presented indicate a quite extensive cross‐neutralization between Brazilian HIV‐1 isolates.

show abstract

Section: Susceptibility To Autologous Neutralizationsupporting

confidence: 84%

Neutralization Susceptibility of B Subtype Variant B′′ Primary HIV‐1 Isolates

Bongertz

et al. 1998

Scand J Immunol

View full text Add to dashboard Cite

show abstract

“…Previous HIV-2 neutralization studies often employed laboratory-adapted virus strains and assay formats that differed from those commonly used to assess HIV-1 NAbs (4, 45,52,56,59). For example, the single-cycle virus entry assay in JC53bl-13/ TZM-bl cells (58) or U87 cells (42) has generally not been used in a comparable assay format to assess HIV-2 NAbs (4,52,56,59). An exception is a study by Rodriguez and colleagues, which employed an HIV-2 Env-pseudotyped HIV-1 (NL4.3) backbone and U87 target cells (45).…”

mentioning

confidence: 99%

“…This study used bulk PCR amplification to generate a quasispecies mixture of Env glycoproteins for neutralization testing. Other studies employed syncytium formation (59), plaque formation (52), or peripheral blood mononuclear cell (PBMC) replication (4,56) as the readout of virus entry. These widely varied approaches have made comparative evaluations of HIV-2 and HIV-1 NAb responses challenging.…”

mentioning

confidence: 99%

Broad and Potent Neutralizing Antibody Responses Elicited in Natural HIV-2 Infection

Kong

Bibollet-Ruche

et al. 2012

J Virol

View full text Add to dashboard Cite

“…HIVspecific cell-mediated immune responses seem to be induced in a larger proportion of HIV-2 carriers than among HIV-1-infected persons (reviewed in reference 2). In addition, it has been reported that autologous neutralizing antibodies prevail in HIV-2 but not in HIV-1 infection (10). Later reports have shown that the neutralizing anti-HIV-2 immunoglobulin G (IgG) antibody response is strain specific and directed against the third variable region (V3) (9,41).…”

mentioning

confidence: 99%

Potent Neutralizing Serum Immunoglobulin A (IgA) in Human Immunodeficiency Virus Type 2-Exposed IgG-Seronegative Individuals

Qin¹,

Nilsson

Sourial

et al. 2004

J Virol

View full text Add to dashboard Cite

The mechanisms behind the resistance to human immunodeficiency virus type 2 (HIV-2) infection are still not fully understood. In the present study, we explored the HIV-2-specific humoral serum immunoglobulin A (IgA) immune response in HIV-2-exposed IgG-seronegative (EGSN) individuals. Serum samples from heterosexual EGSN individuals and their known HIV-2-infected partners, as well as controls originating from Guinea-Bissau in Africa, were studied. Antibody reactivity to native and recombinant envelope glycoproteins was investigated, and the capacity of purified serum IgA to neutralize HIV-2 SBL6669 was tested. Our results showed that 16 of 25 EGSN samples exhibited reactivity against whole HIV-2 antigen, 6 of 25 samples reacted with recombinant gp36 (rgp36), and 3 of 25 samples were positive against HIV-2 rgp105; no reactivity to native HIV-2 gp125 was detected. Purified serum IgA antibodies from both EGSN and HIV-2-positive individuals, but not that from the negative controls, exhibited neutralization of HIV-2 SBL6669 . The most potent neutralization activity was exhibited by IgA purified from EGSN compared to infected individuals' IgA. The antigenic pattern of the HIV-2-positive partners showed that all serum IgA samples were reactive to whole HIV-2 antigen, and 14 of 15 reacted with rgp36. For rgp105 and gp125, 5 of 15 and 4 of 15 samples exhibited binding, respectively. The serum of the EGSN group had a higher mean IgA concentration than that of the negative controls (P < 0.05). Thus, we describe HIV-2-specific serum IgA antigen reactivity and show a more potent serum IgAmediated HIV-2-neutralizing activity in EGSN individuals than in HIV-2-infected patients.

show abstract

Autologous Neutralizing Antibodies Prevail in HIV-2 but Not in HIV-1 Infection

Cited by 83 publications

References 0 publications

Neutralization Susceptibility of B Subtype Variant B′′ Primary HIV‐1 Isolates

Neutralization Susceptibility of B Subtype Variant B′′ Primary HIV‐1 Isolates

Broad and Potent Neutralizing Antibody Responses Elicited in Natural HIV-2 Infection

Potent Neutralizing Serum Immunoglobulin A (IgA) in Human Immunodeficiency Virus Type 2-Exposed IgG-Seronegative Individuals

Contact Info

Product

Resources

About